Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.21 USD
Change Today -0.01 / -0.82%
Volume 229.2K
RGDO On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

regado bioscience inc (RGDO) Snapshot

Open
$1.21
Previous Close
$1.22
Day High
$1.24
Day Low
$1.17
52 Week High
03/31/14 - $13.50
52 Week Low
11/26/14 - $0.80
Market Cap
40.7M
Average Volume 10 Days
442.5K
EPS TTM
$-2.74
Shares Outstanding
33.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGADO BIOSCIENCE INC (RGDO)

Related News

No related news articles were found.

regado bioscience inc (RGDO) Related Businessweek News

No Related Businessweek News Found

regado bioscience inc (RGDO) Details

Regado Biosciences, Inc., a biopharmaceutical company, focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications. The company was formerly known as Quartet Biosciences, Inc. and changed its name to Regado Biosciences, Inc. in March 2003. Regado Biosciences, Inc. was founded in 2001 and is headquartered in Basking Ridge, New Jersey.

4 Employees
Last Reported Date: 02/12/15
Founded in 2001

regado bioscience inc (RGDO) Top Compensated Officers

Chief Executive Officer, President, Chief Ope...
Total Annual Compensation: $178.7K
Compensation as of Fiscal Year 2013.

regado bioscience inc (RGDO) Key Developments

Regado Biosciences, Inc. Announces Board Changes

On February 27, 2015, the Board of Regado Biosciences, Inc. accepted the resignations of B. Jefferson Clark, Anton Gopka, Michael E. Mendelsohn, P. Sherrill Neff, Jesse Treu and Michael Metzger as members of the Board, including as members of any committees or subcommittees of the Board, as applicable, which resignations will be effective as of, and conditioned on, the effective time of the Merger. Mr. Fromkin will continue to serve on the audit committee of the Board and will serve as chair of the compensation committee of the Board, subject to and upon the effective time of the Merger. Mr. Legault will continue to serve as chair of the audit committee. On February 27, 2015, the Board approved the appointment of each of Patrick Heron and Carol L. Brosgart, M.D. to fill the vacancies left by the Class I directors of the company, each of Eckard Weber, M.D., Jeffrey H. Cooper and Gwen A. Melincoff to fill the vacancies left by the Class II directors of the company, and Laurent Fischer, M.D. to fill the vacancy left by the Class III directors of the company, which appointments will be effective as of, and conditioned on, the effective time of the Merger. Patrick Heron has served as a member of Tobira’s board of directors since March 2007. Carol L. Brosgart, M.D, has served as a member of Tobira’s board of directors since September 2009.

Regado Biosciences, Inc., Tobira Therapeutics, Inc. - M&A Call

To discuss the merger agreement

R. Don Elsey to Resign as Senior Vice President, Finance and Chief Financial Officer of Regado Biosciences, Inc., Effective February 6, 2015

On January 3, 2015, R. Don Elsey notified Regado Biosciences, Inc. that he will resign as the company's Senior Vice President, Finance and Chief Financial Officer, effective February 6, 2015. In connection with his resignation as company's Senior Vice President, Finance and Chief Financial Officer, the company and Mr. Elsey plan to enter into a consulting agreement and a separation agreement pursuant to which Mr. Elsey will continue to provide services to the company and to act as the company's principal accounting and financial officer from the effective date of his resignation through the earlier of May 31, 2015 or the company's consummation of certain material corporate transactions, unless earlier terminated or extended.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDO:US $1.21 USD -0.01

RGDO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGDO.
View Industry Companies
 

Industry Analysis

RGDO

Industry Average

Valuation RGDO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGADO BIOSCIENCE INC, please visit www.regadobio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.